CNS Pharmaceuticals Inc

CNS Pharmaceuticals, Inc. is a clinical pharmaceutical company that develops therapies for neurological and oncological diseases in the United States. Its lead candidates are TPI 287, an investigational chemotherapy agent in Phase II trials for glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma, and Berubicin, an investigational anthracycline chemotherapy agent in Phase II trials for glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.

CNSP▼

CNS Pharmaceuticals Q2 GAAP EPS misses estimates by $0.13

CNS Pharmaceuticals reported a second-quarter GAAP loss of $0.37 per share, missing analyst estimates by $0.13. Cash and cash equivalents rose to approximately $20.0 million as of June 30, 2026, up from $7.2 million at the end of 2025, driven mainly by a private placement completed in May 2026. The company believes its existing cash resources are sufficient to fund planned operations beyond the next twelve months as it continues executing its strategic business development initiatives.

CNSP ▼

Seeking Alpha·37dRead more →